Louise Parent - Zoetis Independent Director

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:3em;padding-top: 38px;;'>ZTS</div>
ZTS -- USA Stock  

Report: 6th of August 2020  

Ms. Louise M. Parent is Independent Director of the Company. Ms. Parent has served as Of Counsel at the law firm of Cleary Gottlieb Steen Hamilton LLP. Ms. Parent brings deep experience in corporate governance and board matters, and in compliance and risk management, gained during her tenure with American Express, where she worked extensively with the Audit, Compensation, and Nomination and Governance committees in her role as General Counsel. Ms. Parent also served on the operating committee and global management team of American Express from 2003 through 2013, was a member of the board of American Express Centurion Bank through 2013 and served on the Supervisory Board of Deutsche Bank AG from 2014 to 2018. Ms. Parent currently serves on the board of Fidelity National Information Services Inc., a global financial services technology company. Ms. Parent holds a bachelors degree from Smith College and a law degree from Georgetown University Law Center
Age: 68  Director Since 2013      
973 822-7000  www.zoetis.com
Parent?s experience in corporate governance, compliance, risk management and global management makes her a valuable member of our Board.

Louise Parent Latest Insider Activity

Zoetis Management Efficiency

Zoetis Inc has Return on Asset of 12.48 % which means that on every $100 spent on asset it made $12.48 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 63.55 %, implying that it generated $63.55 on every 100 dollars invested. Zoetis management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. As of 07/13/2020, Return on Sales is likely to grow to 0.28, while Return on Investment is likely to drop 19.96. Zoetis Tax Assets are relatively stable at the moment as compared to the past year. Zoetis reported last year Tax Assets of 110.4 Million. As of 07/13/2020, Revenue to Assets is likely to grow to 0.66, while Current Assets are likely to drop slightly above 4 B. Zoetis Total Liabilities is relatively stable at the moment as compared to the past year. Zoetis reported last year Total Liabilities of 8.84 Billion. As of 07/13/2020, Tax Liabilities is likely to grow to about 470.9 M, while Current Liabilities is likely to drop slightly above 1.5 B.
The company has 6.69 B in debt with debt to equity (D/E) ratio of 2.43, meaning that the company heavily relies on borrowing funds for operations. Zoetis Inc has a current ratio of 2.71, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Dennis AusielloPfizer Inc
Jacqualyn FousePerrigo Company Plc
Gary CohenPerrigo Company Plc
Ellen HoffingPerrigo Company Plc
Bonnie BasslerRegeneron Pharmaceuticals
Joseph GoldsteinRegeneron Pharmaceuticals
Gary KunklePerrigo Company Plc
Omkar GoswamiDr Reddys Laboratories
Alan GarberVertex Pharmaceuticals Incorpor
Bruce CarterDr Reddys Laboratories
Yuchun LeeVertex Pharmaceuticals Incorpor
Michael BrownRegeneron Pharmaceuticals
Helen HobbsPfizer Inc
Suzanne JohnsonPfizer Inc
Jeffrey KindlerPerrigo Company Plc
Huda ZoghbiRegeneron Pharmaceuticals
Michael GallagherAllergan Plc
Geoffrey ParkerPerrigo Company Plc
Allan ObermanDr Reddys Laboratories
Shlomo YanaiPerrigo Company Plc
Ravi BhoothalingamDr Reddys Laboratories

Company Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on BATS Exchange. It employs 10600 people.Zoetis Inc (ZTS) is traded on BATS Exchange in USA and employs 10,600 people.

Zoetis Inc Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director
William Steere, Independent Director
Roxanne Lagano, Chief Human Resource Officer, Executive Vice President and Global Operations
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Did you try this?

Run Theme Ratings Now


Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Also Currentnly Active

<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:1.7em;padding-top:4px;;'>S</div>
Sold over 300 shares of
six days ago
Traded for 8.62
<div class='circular--portrait-small' style='font-weight: 700;background:#347AFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>GM</div>
Sold over 100 shares of
six days ago
Traded for 25.24
<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:0.9em;padding-top: 12px;;'>XOM</div>
Sold over 60 shares of
six days ago
Traded for 44.08
Check out Your Current Watchlist. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page